Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anne Husebekk is active.

Publication


Featured researches published by Anne Husebekk.


Scandinavian Journal of Immunology | 1985

Transformation of Amyloid Precursor SAA to Protein AA and Incorporation in Amyloid Fibrils in Vivo

Anne Husebekk; Bjørn Skogen; Gunnar Husby; G. Marhaug

Experimental amyloidosis was induced in mice by in t raped toneal injections of endotoxin (lipopolysaccharidc (LPS)). In addition to LPS. a group of mice received high‐density lipoprotein (HDL)‐SAA complexes isolated from human acute‐phase serum, whereas a group of control mice received saline in addition to LPS. Isolated amyloid fibrils from the mice given HDL‐SAA contained human AA protein, as shown by immunodiffusion, immunoblot. and enzyme‐linked Immunosorbent assay techniques, in addition to mouse AA. In contrast, amyloid from the control mice contained exclusively AA of mouse origin. Thus, the experiments provided solid evidence that SAA is the precursor for amyloid fibril proiein AA.


Haematologica | 2008

A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn

Mette Kjær Killie; Anne Husebekk; Jens Kjeldsen-Kragh; Bjørn Skogen

Background Neonatal alloimmune thrombocytopenia is most commonly due to transplacental passage of maternal anti-HPA 1a antibodies. A prospective study was carried out to evaluate the pattern and quantity of maternal anti-HPA 1a antibodies in order to predict the level of thrombocytopenia in the neonates. Design and Methods A monoclonal antibody immobilization of platelet antigen assay was used to detect antibodies in maternal samples from 1,990 HPA 1bb women. HLA DRB3*0101 typing was performed in all immunized women by sequencing the HLA DRB3 gene when present. Results Primary immunization more often took place in connection with delivery than during the first pregnancy. There was a strong correlation between maternal antibody levels and the platelet counts in the newborn (R2=0.49, p<0.001). A maternal antibody level above 3.0 IU/mL measured in gestational week 22 or 34 had a diagnostic sensitivity and specificity of 93% and 63%, respectively, for predicting the grade of neonatal thrombocytopenia. The women who were negative for HLA DRB3*0101 had significantly lower anti-HPA 1a antibody levels than those who were HLA DRB3*0101 positive (p<0.007). In contrast to primigravida, in whom anti-HPA 1a antibody levels increased during pregnancy, the antibody level decreased in 92 of 147 women who had been pregnant previously (P92 or more of 147 = 0.003). The anti-HPA 1a antibody level regularly increased after delivery. Conclusions Maternal anti-HPA 1a antibody levels in weeks 22 and 34 of pregnancy are good predictors of the degree of thrombocytopenia in the newborn both in the first and subsequent pregnancies. Most mothers became immunized at the time of delivery.


Scandinavian Journal of Gastroenterology | 2007

Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis

Trine Olsen; Rasmus Goll; Guanglin Cui; Anne Husebekk; Barthold Vonen; Grethe Støa Birketvedt; Jon Florholmen

Objective. The immune characterization of ulcerative colitis (UC) has been unclear and controversial. One possible explanation for the discrepancies between earlier cytokine studies in UC may be the fact that the patients included were on immunosuppressive therapy. Thus, the aim of this study was to determine the tumor necrosis factor-alpha (TNF-α) level and TH1/TH2 cytokine expression (mRNA) profile in patients with untreated UC. Material and methods. Forty-four untreated UC patients, 10 untreated Crohns disease (CD) patients and 28 healthy controls were included in the study. Colon biopsies were processed for quantitative measurements of TNF-α, interleukin (IL)-10, IL-18, IL-4 and interferon-gamma (IFN-γ) mRNA using real-time polymerase chain reaction (PCR). TNF-α expression in T-cell lymphocytes (CD3) and macrophages (CD68) were further characterized by immunohistochemistry (IHC). Results. Compared with the level in normal controls, the TNF-α mRNA level in UC patients was clearly increased, especially in patients with moderate to severe disease. The levels of TNF-α mRNA increased in proportion to the UC Disease Activity Index (UCDAI) score in UC patients. Differences were also observed between UC and controls for IFN-γ IL-18, IL-4 and IL-10. Only minor quantitative differences in cytokines were observed between UC and CD, and they were more or less similar when comparing moderate to severe UC and CD. CD3+ lymphocytes and macrophages in lamina propria from CD and UC lesions showed increased intracellular staining of TNF-α. Conclusions. TNF-α is highly expressed in UC and correlates to the grade of inflammation. The sources of TNF-α were observed both in CD3+ lymphocytes and in macrophages. Cytokine expression (mRNA) profiles seem to be similar in patients with moderate to severe UC and CD.


British Journal of Obstetrics and Gynaecology | 2000

Neonatal alloimmune thrombocytopenia due to anti‐HPA 1a antibodies; the level of maternal antibodies predicts the severity of thrombocytopenia in the newborn

S. Jægtvik; Anne Husebekk; Berit Aune; Pål Øian; L. B. Dahl; Bjørn Skogen

Eleven thousand one hundred pregnant women were genotyped for human platelet antigen HPA 1, and 198 HPA 1bb women were followed in the pregnancy with quantitative assay for anti‐HPA 1a antibodies. Antibodies were detected in 24 women, and nine children were born with severe thrombocytopenia (< 50×109/L). All mothers with high levels of antibodies were delivered of children with severe thrombocytopenia. None of the newborn infants had clinical signs of intra‐cranial haemorrhage. The level of maternal anti‐HPA 1a antibodies is predictive for fetal thrombocytopenia and may be used in decisions related to time and mode of delivery.


Medical Oncology | 2002

Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae.

Tone Nordøy; Ingeborg S. Aaberge; Anne Husebekk; Helvi H. Samdal; Svein Steinert; Hasse Melby; Arne Kolstad

Cancer patients receiving chemotherapy are prone to develop infections that might postpone treatment and lead to complications. The aim of our study was to investigate whether a heterogeneous population of patients with solid tumors and malignant lymphoma undergoing chemotherapy would respond serologically to vaccination against influenza and pneumococcal disease. There are no established routines in oncology departments in Norway regarding vaccination of these patients. The study included 35 cancer patients with median age 53 yr (range 20–74) and 38 controls with median age 57 yr (range 43–75). The chemotherapy regimens used were mild or moderately immunosuppressive. After one vaccination, 25 patients (72%) and 34 controls (87%) were serologically protected against two or three influenza strains. A higher proportion of patients with solid tumors (81%) than lymphoma (38%) achieved protection. Age, months on chemotherapy, and curative versus palliative treatment did not influence responses to vaccination. After vaccination with a 23-valent polysaccharide vaccine against pneumococci, most patients and controls achieved protective serum levels of antibodies against the different serotypes, with the exception that fewer patients were protected against serotype 4. The responses in controls were, however, generally stronger to all serotypes. Tumor type did not influence this vaccination response. We conclude that our cancer patients achieved adequate responses to influenza virus and Streptococcus pneumoniae. These are not live vaccines and are therefore safe for immunocompromised patients. Routine vaccinations against influenza virus and Streptococcus pneumoniae should be considered in cancer patients undergoing mild to moderately immunosuppressive chemotherapy.


Archive | 1991

Amyloid and amyloidosis 1990

Jacob B. Natvig; Øystein Førre; Gunnar Husby; Anne Husebekk; Bjørn Skogen; Knut Sletten; Per Westermark

Amyloid and amyloidosis 1990 , Amyloid and amyloidosis 1990 , کتابخانه دیجیتالی دانشگاه علوم پزشکی و خدمات درمانی شهید بهشتی


Helicobacter | 2007

Helicobacter pylori Stimulates a Mixed Adaptive Immune Response with a Strong T‐Regulatory Component in Human Gastric Mucosa

Rasmus Goll; Franz X. Gruber; Trine Olsen; Guanglin Cui; Gabriele Raschpichler; Magne Buset; Anne Mette Asfeldt; Anne Husebekk; Jon Florholmen

Background:  Host factors play an important role in the pathophysiology of Helicobacter pylori infection and development of gastritis and related disease. The established opinion is that the T‐cell‐mediated immune response to H. pylori infection is of Th1 type. Our earlier immune cell phenotype studies indicate a mixed Th1–Th2 profile of the effector cells. Therefore, an extensive adaptive and regulatory cytokine gene expression profile was conducted by quantitative real‐time polymerase chain reaction (qPCR).


British Journal of Haematology | 2002

Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma

Inger Marie S. Dahl; Thomas Rasmussen; Goran Kauric; Anne Husebekk

Summary. We report on the different expression of CD56 and CD44 in plasma cells (PCs) simultaneously collected from bone marrow, extramedullary locations and peripheral blood in seven patients with multiple myeloma. Extramedullary PCs showed absence of CD56. In the bone marrow, however, subsets with varying CD56 expression were found in five out of seven patients, with one subset corresponding to that of extramedullar PCs. This differs from the de novo downregulation of CD56 in PC leukaemia, and suggests different mechanisms of spread of myeloma cells. CD44 expression was generally upregulated on extramedullary PCs. In three of the patients we investigated the clonal origin of extramedullary myeloma cells by sequencing the variable portion of the heavy chain immunoglobulin gene in phenotypically defined PCs isolated from different locations. In each patient we found malignant PCs with different homing behaviour originating from a common precursor cell.


Scandinavian Journal of Immunology | 1987

Characterization of amyloid proteins AA and SAA as apolipoproteins of high density lipoprotein (HDL). Displacement of SAA from the HDL-SAA complex by apo AI and apo AII.

Anne Husebekk; Bjørn Skogen; Gunnar Husby

An AA‐like protein with a molecular weight of 8600 complexed to high‐density lipoprotein (HDL) was demonstrated in several acute‐phase sera with high levels of SAA. The protein ‘apo AA’(to distinguish it from tissue AA) was isolated by elution from sodium dodecyl sulphate (SDS)‐polyacrylamide gel, and showed antigenic identity with purified tissue protein AA in double immunodiffusion. Normal HDL was shown to bind purified tissue AA in vitro. When the in vitro‐associated HDL‐AA complexes were given intravenously to mice during induction of amyloidosis, human AA was incorporated in the amyloid fibrils. Both apo AI and apo AII were shown to displace SAA from acute phase HDL when added to HDL‐SAA complexes in vitro. This might be of importanee in amyloidogenesis, as the liver and the small intestine, which are the main sites for AI and AII synthesis, are also sites of early amyloid deposition.


BMJ Open | 2013

Fetal intracranial haemorrhages caused by fetal and neonatal alloimmune thrombocytopenia: an observational cohort study of 43 cases from an international multicentre registry

Heidi Tiller; Marije M. Kamphuis; Olof Flodmark; Nikos Papadogiannakis; Anna L. David; Susanna Sainio; Sinikka Koskinen; Kaija Javela; Agneta Wikman; Riitta Kekomäki; Humphrey H.H. Kanhai; Dick Oepkes; Anne Husebekk; Magnus Westgren

Objective To characterise pregnancies where the fetus or neonate was diagnosed with fetal and neonatal alloimmune thrombocytopenia (FNAIT) and suffered from intracranial haemorrhage (ICH), with special focus on time of bleeding onset. Design Observational cohort study of all recorded cases of ICH caused by FNAIT from the international No IntraCranial Haemorrhage (NOICH) registry during the period 2001–2010. Setting 13 tertiary referral centres from nine countries across the world. Participants 37 mothers and 43 children of FNAIT pregnancies complicated by fetal or neonatal ICH identified from the NOICH registry was included if FNAIT diagnosis and ICH was confirmed. Primary and secondary outcome measures Gestational age at onset of ICH, type of ICH and clinical outcome of ICH were the primary outcome measures. General maternal and neonatal characteristics of pregnancies complicated by fetal/neonatal ICH were secondary outcome measures. Results From a total of 592 FNAIT cases in the registry, 43 confirmed cases of ICH due to FNAIT were included in the study. The majority of bleedings (23/43, 54%) occurred before 28 gestational weeks and often affected the first born child (27/43, 63%). One-third (35%) of the children died within 4 days after delivery. 23 (53%) children survived with severe neurological disabilities and only 5 (12%) were alive and well at time of discharge. Antenatal treatment was not given in most (91%) cases of fetal/neonatal ICH. Conclusions ICH caused by FNAIT often occurs during second trimester and the clinical outcome is poor. In order to prevent ICH caused by FNAIT, at-risk pregnancies must be identified and prevention and/or interventions should start early in the second trimester.

Collaboration


Dive into the Anne Husebekk's collaboration.

Top Co-Authors

Avatar

Bjørn Skogen

University Hospital of North Norway

View shared research outputs
Top Co-Authors

Avatar

Mette Kjær Killie

University Hospital of North Norway

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Heidi Tiller

University Hospital of North Norway

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Maria Therese Ahlen

University Hospital of North Norway

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rasmus Goll

University Hospital of North Norway

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge